Evaluation of Cefixime and Ofloxacin as an Adjunct to Scaling and Root Planing in the Treatment of Generalized Chronic Periodontitis: A Clinicomicrobiological Study
Citation Information :
Pashupatimath S, Babu HM, Rangaraju VM, Sadanandan S. Evaluation of Cefixime and Ofloxacin as an Adjunct to Scaling and Root Planing in the Treatment of Generalized Chronic Periodontitis: A Clinicomicrobiological Study. World J Dent 2024; 15 (6):520-525.
Aim and objectives: The present study aimed to evaluate the clinical and microbiological effects of the cefixime-ofloxacin combination as an adjunct to scaling and root planing (SRP) in the treatment of chronic periodontitis.
Materials and methods: Forty subjects, aged 30–60 years, with generalized chronic periodontitis were selected. They were randomly assigned and divided into the following two groups: a test group, which received cefixime-ofloxacin combination therapy along with SRP, and a control group receiving SRP alone. Gingival index (GI), papillary bleeding index (PBI), and probing pocket depth (PPD) scores were recorded at baseline and the 90th day. Saliva samples were collected at baseline and the 90th day and inoculated on sheep blood medium. Colonies were observed for their morphology and counted using a digital colony counter.
Results: Both groups showed a reduction in GI, PBI, mean PPD, and microbial colony counts from baseline to 3 months, with better improvement in scores observed in the SRP + cefixime-ofloxacin combination group compared to the SRP alone group. The intergroup comparison of GI, PBI, mean PPD, and microbial colony counts at baseline and 3 months showed a statistically significant difference.
Conclusion: Cefixime-ofloxacin combination therapy proved to be an effective adjunct to SRP in the treatment of generalized chronic periodontitis. This combination was safe and well tolerated by patients.
Clinical significance: The cefixime-ofloxacin combination acts on a wide range of periodontal pathogens and has fewer side effects, making it safe for administration as an adjunct to SRP in the treatment of generalized chronic periodontitis.
Dukic S, Matijevic S, Dakovic D, et al. Comparison of cefixime and amoxicillin plus metronidazole in the treatment of chronic periodontitis. Vojnosanit Pregl 2016;73:526–530. DOI: 10.2298/vsp150326133d
Paul GT, Gandhimadhi D, Babu SP. A double-blind, placebo controlled study to assess the clinical and microbiological effects of a probiotic lozenge as an adjunctive therapy in the management of chronic periodontitis. J Health Res 2019;6:57–63. DOI: 10.4103/cjhr.cjhr_71_18
Saglie FR, Carranza FA, Newman MG, et al. Identification of tissue-invading bacteria in human periodontal disease. J Periodontol Res 1982;17:452–455. DOI: 10.1111/j.1600-0765.1982.tb02024.x
Walker CB. The acquisition of antibiotic resistance in the periodontal microflora. Periodontol 2000 1996;10:79–88. DOI: 10.1111/j.1600-0757.1996.tb00069.x
Patil V, Mali R, Mali A. Systemic anti-microbial agents used in periodontal therapy. J Indian Soc Periodontol 2013;17:162–168. DOI: 10.4103/0972-124X.113063
Drlica K, Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev 1997;61:377–392. DOI: 10.1128/mmbr.61.3.377-392.1997
Tanner A, Maiden MF, Paster BJ. The impact of 16S ribosomal RNA-based phylogeny on the taxonomy of oral bacteria. Periodontol 2000 1994;5:26–51. DOI: 10.1111/j.1600-0757.1994.tb00017.x
Kleinfelder JW, Muller RF, Lange DF. Fluoroquinolones in the treatment of Actinobacillus actinomycetemcomitans associated periodontitis. J Periodontol 2000;71:202–208. DOI: 10.1111/j.1600-0757.1994.tb00017.x
Aas JA, Paster BJ, Stokes LN, et al. Defining the normal bacterial flora of the oral cavity. J Clin Microbiol 2005;43:5721–5732. DOI: 10.1128/JCM.43.11.5721-5732.2005
Choi Y, Lee J, Choi J, et al. Effect of root planing on the reduction of probing depth and the gain of clinical attachment depending on the mode of interproximal bone resorption. J Periodontal Implant Sci 2015;45:184–189. DOI: 10.5051/jpis.2015.45.5.184
Plessas A. Nonsurgical periodontal treatment: review of the evidence. Oral Health Dent Manag 2014;13:71–80. PMID: 24603920.
Barca E, Cifcibasi E, Cintan S. Adjunctive use of antibiotics in periodontal therapy. J Istanbul UnivFac Dent 2015;49:55–62. DOI: 10.17096/jiufd.90144
Boid A, Muglikar S, Hegde R. A comparative evaluation of systemic azithromycin and ornidazole - ofloxacin combination as an adjunct to scaling and root planing in the treatment of chronic generalised periodontitis. Dentistry 2015;5:5–7. DOI: 10.4172/2161-1122.1000309
Kapoor A, Malhotra R, Grover V, et al. Systemic antibiotic therapy in periodontics. Dent Res J 2012;9:505–515. DOI: 10.4103/1735-3327.104866
Gibson W. Antibiotics and periodontal disease: a selective review of the literature. J Am Dent Assoc 1982;104:213–218. DOI: 10.14219/jada.archive.1982.0029
Prakasam A, Elavarasu S, Natarajan R. Antibiotics in the management of aggressive periodontitis. J Pharm Bioallied Sci 2012;4:252–255. DOI: 10.4103/0975-7406.100226
Wolfson JS, Hooper DC. The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob Agents Chemother 1985;28:581–586. DOI: 10.1128/aac.28.4.581
Hooper DC, Wolfson JS. The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans. Antimicrob Agents Chemother 1985;28:716–721. DOI: 10.1128/AAC.28.5.716
Miyake Y, Onoe T, Sagawa H. In vitro antibacterial activity of ofloxacin against periodontal disease-associated bacteria. J Periodont Res 1988;23:222–223. DOI: 10.1111/j.1600-0765.1988.tb01361.x
Yamagami H, Takamori A, Sakamoto T, et al. Intrapocket chemotherapy in adult periodontitis using a new controlled-release insert containing ofloxacin (PT-01). J Periodontol 1992;63:2–6. DOI: 10.1902/jop.1992.63.1.2
